English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Polymorphisms in the genes encoding CYP2C9 enzyme and VKORC1 reductase significantly influence the dose variability of coumarinic oral anticoagulants (COAs). Substantial inter- and intraethnic variability exists in the frequencies of  CYP2C9∗   2 and    ∗   3 and  VKORC1  –1639A alleles. However, the prevalence of  CYP2C9  and  VKORC1  genetic variants is less characterized in Arab populations. A total of 131 healthy adult subjects from the Al-Ahsa region of Saudi Arabia were genotyped for the  CYP2C9∗   2 and    ∗   3 and  VKORC1  –1639G>A polymorphisms by PCR-RFLP method. The frequencies of the  CYP2C9∗   2 and    ∗   3 and  VKORC1  –1639A alleles were 13.3%, 2.3%, and 42.4%, respectively, with no subjects carrying 2 defective alleles. The frequencies of the  CYP2C9∗   3 and  VKORC1  –1639A alleles were significantly lower than those reported in different Arabian populations. None of the subjects with the  VKORC1  –1639AA genotype were carriers of  CYP2C9∗   1/   ∗   3 genotypes that lead to sensitivity to COAs therapy. The low frequency of the  CYP2C9∗   3 allele combined with the absence of subjects carrying 2 defective  CYP2C9  alleles suggests that, in this specific population, pharmacogenetic COAs dosing may mostly rely upon  VKORC1  genotyping.

Genotyping ofCYP2C9andVKORC1in the Arabic Population of Al-Ahsa, Saudi Arabia